Luis Rico | Oncology | Editorial Board Member

Published on 03/12/202503/12/2025 by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on 03/12/202503/12/2025 by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Jun Lu | Cancer | Editorial Board Member

Published on 03/12/202503/12/2025 by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on 03/12/202503/12/2025 by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on 30/10/202530/10/2025 by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Rami Ahmad | Cancer Therapy | Best Researcher Award

Published on 15/10/202515/10/2025 by Oncology

Prof. Dr. Rami Ahmad | Cancer Therapy | Best Researcher Award

Senior Researcher | Czech Education and Scientific Network | Czech Republic

Prof. Dr. Rami Ahmad El-Nabulsi is a distinguished theoretical physicist and applied mathematician whose research bridges nonlinear quantum dynamics, fractal mechanics, plasma and solid-state physics, and advanced mathematical modeling. Holding a PhD in Particle and Mathematical Physics from AMU, along with postgraduate diplomas in Plasma Physics and degrees in Physics at both master’s and bachelor’s levels, he has built a prolific career combining theoretical rigor with computational innovation. He is currently affiliated with the Center of Excellence in Quantum Technology, Faculty of Engineering, and the Quantum-Atom Optics Laboratory at Chiang Mai University, Thailand, as well as with the University of South Bohemia and the Department of Optical Networks CESNET in the Czech Republic. Prof. El-Nabulsi’s research interests encompass geometrical and quantum dynamics, nonlinear systems, chaos and bifurcations, general relativity, quantum field theory, and the application of fractional and fractal calculus to complex systems in engineering, astrophysics, and materials science. His expertise extends to advanced computational modeling, partial differential equations, stochastic systems, and numerical simulations. He has received multiple international honors, including the Outstanding Scientist Research Award and the Lifetime Achievement Award. A reviewer for more than 250 scientific journals and an editorial board member in over 40 peer-reviewed publications, he has authored more than 390 research articles in high-impact international journals and is frequently invited as an honorary speaker at global conferences. Prof. El-Nabulsi’s academic dedication, multidisciplinary approach, and sustained research excellence continue to shape theoretical and applied physics worldwide. His scholarly impact is reflected in 4,873 citations, 277 documents, and an h-index of 35, underscoring his influential role in advancing modern fractal physics and nonlinear dynamical systems research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. El-Nabulsi, R. A., & Anukool, W. (2025). Chaotic and fractal maps in higher-order derivative dynamical systems. Frontiers in Physics, 12, 1529644. Cited by: 8

2. El-Nabulsi, R. A., & Anukool, W. (2025). Qualitative financial modelling in fractal dimensions. Financial Innovation, 11, 42. Cited by: 6

3. El-Nabulsi, R. A. (2025). A fractional model to study soliton in presence of charged space debris at low-Earth orbital plasma region. IEEE Transactions on Plasma Science, 52(9), 4671–4693. Cited by: 4

4. El-Nabulsi, R. A., & Golmankhaneh, A. K. (2025). Propagation of waves in fractal spaces. Waves in Random and Complex Media. Cited by: 4

5. El-Nabulsi, R. A., & Anukool, W. (2025). Vlasov equation, waves and dispersion relations in fractal dimensions: Landau damping and the toroidal ion temperature gradient instability problem. Waves in Random and Complex Media. Cited by: 14

6. El-Nabulsi, R. A. (2024). Transition from circular to spiral waves and from Mexican hat to upside-down Mexican hat-solutions: The cases of local and nonlocal λ–ω reaction–diffusion–convection fractal systems with variable coefficients. Chaos, Solitons & Fractals, 189, 115737. Cited by: 3

7. El-Nabulsi, R. A. (2024). Modelling nematic liquid crystal in fractal dimensions. Medicine in Novel Technology and Devices, 24, 100334. Cited by: 7

Yubing Wang | Oncology | Best Researcher Award

Published on 10/02/202510/02/2025 by Oncology

Assoc. Prof. Dr. Yubing Wang | Oncology | Best Researcher Award

Weifang No.2 People’s Hospital | China

AUTHOR PROFILE

Scopus

🔬 EARLY ACADEMIC PURSUITS

Yubing Wang embarked on his academic journey with a strong foundation in biosciences. In 2007, he earned his Bachelor’s degree in Bioscience from Shandong University, which laid the groundwork for his future endeavors in the field of biological and medical sciences. His passion for scientific research led him to pursue further studies, culminating in a Doctor of Science degree from The Chinese University of Hong Kong in 2017. This rigorous academic training provided him with expertise in advanced biological sciences and research methodologies, setting the stage for his future contributions to medical and bioscience research.

🏥 PROFESSIONAL ENDEAVORS

Dr. Wang’s professional career is marked by significant roles in both research and academia. His journey began as a Research Assistant at the Shanghai Institutes for Biological Sciences, CAS, where he worked for six years (2007–2013), gaining hands-on experience in cutting-edge biological research. Following this, he transitioned into academia, taking on the role of Associate Professor at Shandong Second Medical University from 2018 to 2023. His commitment to teaching and research was further recognized when he joined Weifang No.2 People’s Hospital as an Associate Professor in 2023, where he continues to contribute to the advancement of medical sciences.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY

Dr. Wang’s research is centered around biosciences and medical applications, particularly in biological mechanisms and therapeutic developments. His work has contributed to a deeper understanding of biomedical sciences, with a focus on improving clinical outcomes through innovative research. His interdisciplinary approach combines molecular biology, biotechnology, and clinical applications, addressing critical medical challenges and advancing healthcare solutions.

🌍 IMPACT AND INFLUENCE

Throughout his career, Dr. Wang has played a pivotal role in bridging the gap between fundamental bioscience research and its practical applications in medicine. His work has influenced both the academic community and clinical practices, contributing to the development of novel medical treatments and diagnostic tools. By mentoring students and collaborating with fellow researchers, he has fostered a new generation of scientists committed to pushing the boundaries of medical research.

📖 ACADEMIC CITATIONS AND RECOGNITION

Dr. Wang’s research has been widely recognized in the academic community, with numerous scientific publications in reputed journals. His work has been cited by fellow researchers, reflecting the significance and impact of his contributions to biosciences and medical research. His research has also been instrumental in guiding clinical practices and informing new treatment methodologies.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

As an esteemed academic and researcher, Dr. Wang continues to expand his influence in bioscience and medical research. His future endeavors aim to enhance interdisciplinary research collaborations, further the development of innovative healthcare solutions, and mentor the next generation of scientists and medical professionals. His work at Weifang No.2 People’s Hospital is expected to drive forward transformative research, ultimately improving patient care and advancing medical knowledge.

🏆 CONCLUSION

Dr. Yubing Wang’s career exemplifies a commitment to scientific excellence, academic mentorship, and transformative medical research. His contributions in biosciences and medicine have left a lasting impact on both academia and clinical practice. With his expertise and dedication, he continues to shape the future of biomedical research, paving the way for groundbreaking discoveries and improved healthcare outcomes. His legacy as a researcher and educator ensures that his influence will be felt for generations to come.

📊🔬NOTABLE PUBLICATION:

Title: Improved efficacy of cisplatin delivery by peanut agglutinin‑modified liposomes in non‑small cell lung cancer
Authors: B., Yang, Ben , R., Kou, Rongguan , H., Wang, Hui , … W., Yu, Wenjing , Z., Gao, Zhiqin
Journal: International Journal of Molecular Medicine
Year: 2024

Title: Novel analgesic peptide derived from Cinobufacini injection suppressing inflammation and pain via ERK1/2/COX-2 pathway
Authors: L., Guo, Li , S., Zhang, Sai , C., Zhang, Cong , … Y., Gao, Yuanyuan , T., Sun, Tongyi
Journal: International Immunopharmacology
Year: 2024

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Published on 12/10/202412/10/2024 by Oncology

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Liaoning University | China

Author Profile

Scopus

🌟 Professor Hongsheng Liu: A Pioneer in Microbiology and Bioinformatics

Professor, School of Pharmaceutical Sciences, Liaoning University, China

🔬 Academic and Professional Background

Professor Hongsheng Liu obtained a Master’s degree in Microbiology from China Agricultural University in 1991 and later pursued a Ph.D. in Microbiology and Bioinformatics at Gifu University School of Medicine, Japan, in 2004. Over the years, he has expanded his expertise by serving as a visiting scholar at prestigious institutions such as Wuhan University, the University of Hong Kong, Harvard Medical School, and Hebrew University of Jerusalem. His career reflects a deep commitment to advancing the fields of microbiology, bioinformatics, and pharmaceutical sciences.

💡 Research and Innovations

Professor Liu has completed an impressive 74 research projects and authored over 100 journal articles (SCI, Scopus, etc.), accumulating a citation index of 2721. His work spans diverse areas, including the discovery of the novel microorganism Paenibacillus liaoningensis sp. nov. and the investigation of influenza virus interactions. His contributions to computational biology include the development of several predictive algorithms and online platforms like CarcinoPred-EL and LiverToxPred-EL. Additionally, Professor Liu holds 37 patents, has published 4 books, and has led 7 industry consultancy projects.

📚 Published Works and Collaborations

Professor Liu’s collaborative research includes partnerships with renowned institutions such as the University of Toledo, Harvard Medical School, and Eberhard Karl University of Tübingen. He has also served as a guest editor for Frontiers in Microbiology (2017-2018). His dedication to both basic and applied research continues to push the boundaries of pharmaceutical sciences.

👥 Professional Memberships

He is an active member of the Chinese Society for Microbiology (CSM) and the Chinese Chemical Society (CCS).

🌍 Areas of Research

Professor Liu specializes in computer-aided drug design and the simulation of biomacromolecule interactions, with a focus on studying lncRNAs and disease relationships, and designing stable recombinant proteins using engineered bacteria.

🔔 Conclusion

Professor Hongsheng Liu stands as a distinguished leader in microbiology and bioinformatics, contributing significantly to drug design, biomolecular simulation, and microbial discovery. His broad academic collaborations, cutting-edge innovations, and vast research output underscore his influence in the scientific community. Through his extensive work on predictive algorithms, microbial databases, and recombinant protein design, he has made impactful advancements in pharmaceutical sciences. With over 100 journal publications, 37 patents, and numerous prestigious collaborations, Professor Liu’s dedication to advancing scientific knowledge and improving human health is truly commendable.

📊🔬NOTABLE PUBLICATION:

- Article Title: Ensemble multiclassification model for aquatic toxicity of organic compounds
  Authors: Li, X., Liu, G., Wang, Z., Liu, H., Ai, H.
  Journal: Aquatic Toxicology
  Year: 2023
- Article Title: Construction of an oxidative stress-related lncRNAs signature to predict prognosis and the immune response in gastric cancer
  Authors: Zhang, H., Feng, H., Yu, T., Ma, L., Liu, H.
  Journal: Scientific Reports
  Year: 2023
- Article Title: CBIL-VHPLI: a model for predicting viral-host protein-lncRNA interactions based on machine learning and transfer learning
  Authors: Zhang, M., Zhang, L., Liu, T., Zhao, J., Liu, H.
  Journal: Scientific Reports
  Year: 2024
- Article Title: Construction of highly active and stable recombinant nattokinase by engineered bacteria and computational design
  Authors: Wang, L., Meng, J., Yu, X., Zhang, L., Liu, H.
  Journal: Archives of Biochemistry and Biophysics
  Year: 2024
- Article Title: Effects of dietary supplementation of gallic tannic acid on growth, intestinal digestive enzymes activity, innate immunity, morphology, and microbial composition of Cyprinus carpio
  Authors: Feng, H., Zhao, S., Ma, X., Liu, Z., Liu, H.
  Journal: Aquaculture International
  Year: 2024

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

Published on 07/08/202407/08/2024 by Oncology

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

National Conservatory of Arts and Crafts | France

Author Profile

Scopus

Google Scholar

Biography: Dr. Abdulhadi ALJAWISH

🧑‍🔬 Education

2009-2013: Ph.D. in Biotechnological and Food Processes (with Honors)
Laboratoire d’Ingénierie des Biomolécules-ENSAIA, Université de Lorraine, Nancy, France
Thesis: “Enzymatic functionalization of chitosan with phenolic compounds by Myceliophthora thermophila laccase”
Advisors: Prof. Joël SCHER, Prof. Isabelle CHEVALOT
Defense Date: 08/07/2013

2008-2009: Master’s in Biotechnology, Agro-resources, Food, Nutrition (B.A.A.N) (with Merit)
Laboratoire de Biocatalyse-Bioprocédés (LBB), ENSAIA-INPL, Nancy, France
Research: “Enzymatic synthesis of natural colorants from phenolic compounds”
Advisors: Prof. Michel GIRARDIN, Dr. Lionel MUNIGLIA

👨‍💼 Professional Experience

2021-2023: Head of Research & Development in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2019-2021: Research & Development Engineer in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2016-2018: Postdoctoral Fellow in Biocatalysis – Bioprocesses
Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2015-2016: Postdoctoral Fellow in Biochemistry – Toxicology
Institut de Chimie Moléculaire (ICMUB-UMR-CNRS6302), Université de Bourgogne, Dijon, France
Laboratoire de Nutrition et Toxicologie (NuTox), INSERM -UMR U866-Agrosup, Dijon, France

2013-2015: Temporary Teaching and Research Attaché (ATER) in Biochemistry – Food Biotechnology
École nationale supérieure d’agronomie et des industries alimentaires (ENSAIA), Université de Lorraine, Nancy, France

2009-2013: Ph.D. Researcher in Biotechnology and Food Processes
Laboratoire d’Ingénierie des Biomolécules (LIBio), Laboratoire Réactions et Génie des procédés (LRGP)-ENSAIA, Université de Lorraine, Nancy, France

📚 Supervision and Collective Responsibilities

Supervised several Master’s and Ph.D. students in various projects related to enzymatic purification, functionalization, and biotests development.
Managed projects on the valorization of food waste and biodiesel by-products, emphasizing circular economy principles.

🧬 Skills and Expertise

Circular Economy: Valorization of food waste and biomass, biodiesel production, energy recovery.
Biosynthesis/Biocatalysis: Enzyme purification and characterization, oxidative processes, esterification, transesterification, kinetic studies, various enzymes like lipase, polyphenol oxidases, cellulase, amidase, and decarboxylase.
Structural Characterization: UV-Vis spectroscopy, HPLC, LC-MS, GC-MS, FT-IR, NMR.
Industrial Processes: Extraction, purification, separation, sterilization, pasteurization, atomization, evaporation, lyophilization.
Physicochemical Properties: Particle size, color parameters, viscosity, thickness, zeta potential, melting and boiling points, colloidal stability, water sorption isotherms, thermal properties.
Biochemistry: Antioxidant tests, microbiological assays, cell culture, cytotoxicity, genotoxicity, biocompatibility, polymer chemistry, food analysis.
Technical Skills: Expertise with various analytical instruments and techniques, including FT-IR, NMR, HPLC, LC-MS, SEM, TEM, and many others.
Statistical Analysis: ANOVA, Duncan’s Multiple Range tests.
Certifications: Management, Biotechnology, Life Cycle Analysis (SimaPro).

🌐 Language and Computer Proficiency

Languages:
- French (Fluent)
- English (Fluent)
- Arabic (Native)
Computer Skills:
- Microsoft Office (Word, Excel, PowerPoint)

This summary encapsulates the academic and professional journey of Abdulhadi ALJAWISH, emphasizing his vast experience in biotechnological processes, food science, and enzymatic applications.

📊🔬Notable Publication:

Bioprocesses for the Biodiesel Production from Waste Oils and Valorization of Glycerol
- Authors: Decarpigny, C., Aljawish, A., His, C., Millares, M., Froidevaux, R.
- Journal: Energies
- Year: 2022

Green synthesis of glyco-phenol by enzymatic coupling between ferulic acid and glucosamine: An ecofriendly procedure
- Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
- Journal: Biotechnology and Applied Biochemistry
- Year: 2022

Enzymatic Oxidation of Ferulic Acid as a Way of Preparing New Derivatives
- Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
- Journal: BioTech
- Year: 2022

Comparing the efficiency of extracting antioxidant polyphenols from spent coffee grounds using an innovative ultrasound-assisted extraction equipment versus conventional method
- Authors: Beaudor, M., Vauchel, P., Pradal, D., Aljawish, A., Phalip, V.
- Journal: Chemical Engineering and Processing – Process Intensification
- Year: 2023

Synthesis and characterization of release agent from used cooking oil at the concrete/formwork interface
- Authors: Libessart, L., Anceur, R., Djelal, C., Aljawish, A., Millares, M.
- Journal: International Journal of Environmental Science and Technology
- Year: 2023

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Published on 11/01/202419/02/2024 by Oncology

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023